	US 12,274,748 B2
	Adenoviral vector transduced apheresis product
Patrick Soon-Shiong, Culver City, CA (US); Elizabeth Gabitzsch, Culver City, CA (US); and Philip T. Liu, Culver City, CA (US)
Assigned to ImmunityBio, Inc., Culver City, CA (US)
Filed by ImmunityBio, Inc., Culver City, CA (US)
Filed on Apr. 29, 2024, as Appl. No. 18/649,790.
Claims priority of provisional application 63/500,235, filed on May 4, 2023.
Prior Publication US 2024/0366764 A1, Nov. 7, 2024
Int. Cl. A61K 40/15 (2025.01); A61K 40/24 (2025.01); A61K 40/42 (2025.01); C07K 14/47 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01)

CPC A61K 40/4201 (2025.01) [A61K 40/15 (2025.01); A61K 40/24 (2025.01); C07K 14/4748 (2013.01); C12N 5/0646 (2013.01); C12N 15/86 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/26 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/10362 (2013.01)]

6 Claims

1. An immunotherapeutic composition, comprising:

1) Subject-derived peripheral blood mononuclear cells (PBMC), granulocyte macrophage colony stimulating factor (GM-CSF), and FMS-like tyrosine kinase 3 (Flt-3) ligand,

2) at least one recombinant adenovirus subtype 5 (Ad5) vector comprising a deletion in an E1 gene region, a deletion in an E2b gene region, and a nucleic acid sequence encoding a peptide antigen, and

2) Immune-stimulating cytokines comprising a) Interleukin-15 (IL-15) or an IL-15: IL-15 receptor alpha (IL15: IL15Rα) complex, b) IL-2, and c) IL-7,

wherein the PBMC are simultaneously exposed to the Ad5 vector and the immune stimulating cytokines.